In vivo protection by broadly neutralizing HIV antibodies

Trends in Microbiology

Volumn 22, Issue 10, 2014, Pages 550-551

  van Gils, Marit J ^a   Sanders, Rogier W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10E8 ANTIBODY; 2D5 ANTIBODY; 2F5 ANTIBODY; 4E10 ANTIBODY; BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IBALIZUMAB; PG9 ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VRC01 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

DRUG POTENCY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; RHESUS MONKEY; SHORT SURVEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MACACA MULATTA;

EID: 84908477298     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.08.006     Document Type: Short Survey

References (10)

1. van Gils M.J., Sanders R.W. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013, 435:46-56.
2. Berkhout B., Sanders R.W. Gene therapy as a vaccine for HIV-1. Expert Opin. Biol. Ther. 2012, 12:1315-1321.
3. Pegu A., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 2014, 6:243ra288.
4. Fessel W.J., et al. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. Antiviral Res. 2011, 92:484-487.
5. Parren P.W.H.I., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8240-8347.
6. Hessell A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
7. Mascola J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
8. Moldt B., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:18921-18925.
9. Lewis G.K., et al. Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Curr. Opin. HIV AIDS 2014, 9:263-270.
10. Hessell A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.